Why is C4 Therapeutics suddenly up 135%?
C4 Therapeutics Announces License And Research Collaboration With Merck For Degrader-Antibody Conjugates, C4T Will Receive $10M Upfront Payment and Is Eligible For Milestone Payment Of $600M
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Stock_Drift : I bought in low.